222 related articles for article (PubMed ID: 22918928)
1. Evolution of end points for cancer immunotherapy trials.
Hoos A
Ann Oncol; 2012 Sep; 23 Suppl 8():viii47-52. PubMed ID: 22918928
[TBL] [Abstract][Full Text] [Related]
2. Improved endpoints for cancer immunotherapy trials.
Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
[TBL] [Abstract][Full Text] [Related]
3. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
4. Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.
Mick R; Chen TT
Cancer Immunol Res; 2015 Dec; 3(12):1292-8. PubMed ID: 26644449
[TBL] [Abstract][Full Text] [Related]
5. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
6. Cancer vaccines: what do we need to measure in clinical trials?
Kudrin A
Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
[TBL] [Abstract][Full Text] [Related]
7. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
8. Can immuno-oncology offer a truly pan-tumour approach to therapy?
Eggermont AM
Ann Oncol; 2012 Sep; 23 Suppl 8():viii53-7. PubMed ID: 22918930
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
10. Design of clinical trials for therapeutic cancer vaccines development.
Mackiewicz J; Mackiewicz A
Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
[TBL] [Abstract][Full Text] [Related]
11. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Galon J; Bruni D
Nat Rev Drug Discov; 2019 Mar; 18(3):197-218. PubMed ID: 30610226
[TBL] [Abstract][Full Text] [Related]
12. A second chance for telomerase reverse transcriptase in anticancer immunotherapy.
Zanetti M
Nat Rev Clin Oncol; 2017 Feb; 14(2):115-128. PubMed ID: 27245281
[TBL] [Abstract][Full Text] [Related]
13. Addressing cancer immunotherapy research in Iran: adoptive cell therapy on the horizon.
Khatami F; Torabi-Rahvar M; Kiani J; Naderi M; Ahmadbeigi N
Cytotherapy; 2018 Oct; 20(10):1227-1237. PubMed ID: 30266521
[TBL] [Abstract][Full Text] [Related]
14. Surrogate markers of response to cancer immunotherapy.
Morse MA; Clay TM; Hobeika AC; Mosca PJ; Lyerly HK
Expert Opin Biol Ther; 2001 Mar; 1(2):153-8. PubMed ID: 11727526
[TBL] [Abstract][Full Text] [Related]
15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
16. [New directions in immunotherapy for malignant solid tumors].
Okuno K; Sugiura F; Sukegawa Y; Inoue K
Nihon Rinsho; 2012 Dec; 70(12):2075-86. PubMed ID: 23259377
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy: Breakthrough or "deja vu, all over again"?
Sell S
Tumour Biol; 2017 Jun; 39(6):1010428317707764. PubMed ID: 28639883
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic cancer vaccines: at midway between immunology and pharmacology.
Lage A; Perez R; Fernandez LE
Curr Cancer Drug Targets; 2005 Dec; 5(8):611-27. PubMed ID: 16375666
[TBL] [Abstract][Full Text] [Related]
19. PROSTVAC® targeted immunotherapy candidate for prostate cancer.
Shore ND
Immunotherapy; 2014; 6(3):235-47. PubMed ID: 24762070
[TBL] [Abstract][Full Text] [Related]
20. Current status and future prospects of peptide-based cancer vaccines.
Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
